Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Tolerogenic dendritic cells produced by Lentiviral-mediated CD40- and IL-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing Th17 cells.
Empyema presenting as lower extremity weakness.
Epstein-barr virus: the path from association to causality for a ubiquitous human pathogen.
Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
Remotely-supervised transcranial direct current stimulation (tDCS) for clinical trials: guidelines for technology and protocols.
Inhibition of Interferon regulatory factor 4 Suppresses Th1 and Th17 Cell Differentiation and Ameliorates Experimental Autoimmune Encephalomyelitis.
Prognostic factors of acute partial transverse myelitis-reply.
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients.
Live cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivo.
Improving adherence to injectable disease-modifying drugs in multiple sclerosis.
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study.
Three-dimensional ultra-structures of myelin and the axons in the spinal cord: Application of SEM with the osmium maceration method to the central nervous system in two mouse models.
Surgery and risk for multiple sclerosis: a systematic review and meta-analysis of case-control studies.
Natalizumab: Bench to Bedside and Beyond.
TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.
Therapeutic efficacy of erythropoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis.
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.
Neurosarcoidosis as an MS Mimic: The trials and tribulations of making a diagnosis.
Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins.
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells.
Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis.
Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases.
Myelin organization in the nodal, paranodal, and juxtaparanodal regions revealed by scanning x-ray microdiffraction.
Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
Pages
« first
‹ previous
…
395
396
397
398
399
400
401
402
403
…
next ›
last »